MARKET

SLXNW

SLXNW

Silexion Therapeutics Corp
NASDAQ
0.0330
0.0000
0.00%
Closed 09:30 12/05 EST
OPEN
0.0330
PREV CLOSE
0.0330
HIGH
0.0330
LOW
0.0330
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.1100
52 WEEK LOW
0.0139
MARKET CAP
--
P/E (TTM)
-0.0013
1D
5D
1M
3M
1Y
5Y
1D
BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical
Reuters · 5d ago
SILEXION THERAPEUTICS CORP - REGULATORY SUBMISSIONS IN ISRAEL BY Q4 2025, GERMANY BY Q1 2026
Reuters · 5d ago
SILEXION THERAPEUTICS CORP - ON TRACK TO INITIATE PHASE 2/3 TRIAL IN H1 2026
Reuters · 5d ago
Silexion Therapeutics Unveils Gene Silencing Breakthroughs Targeting KRAS-Driven Cancers
Reuters · 5d ago
Weekly Report: what happened at SLXNW last week (1124-1128)?
Weekly Report · 6d ago
BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026
Reuters · 11/25 16:46
Silexion Therapeutics Reports Successful Toxicology Results for SIL204 in Pancreatic Cancer
Reuters · 11/25 14:32
Silexion Therapeutics to Launch Phase 2/3 Trial of SIL204 in Pancreatic Cancer
Reuters · 11/25 14:26
More
About SLXNW
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXNW stock methods without spending real money on the virtual paper trading platform.